This page shows the latest alemtuzumab news and features for those working in and with pharma, biotech and healthcare.
For 2019 as a whole it topped 2.1bn in sales. Sanofi already has an established MS franchise with oral therapy Aubagio (teriflunomide) and Lemtrada (alemtuzumab), but that declined 3% to
This includes Sanofi Genzyme’s multiple sclerosis medicine Lemtrada(alemtuzumab), which now has restricted use due to reports of rare but serious side effects, including death.
The dispute centres on Lemtrada (alemtuzumab) and specifically the regulatory and sales milestone payments that were due Genzyme shareholders as part of Sanofi’s $20bn takeover of Genzyme in 2011, when
It also has high hopes for alemtuzumab in primary progressive MS, Regeneron-partnered cemiplimab for first-line non-small cell lung cancer and SAR425899, a GLP-1/GCR dual agonist that
the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.
Prolia/Xgeva (denosumab) and Vectibix (panitumumab), Novartis' Xolair (omalizumab) and Sanofi's Campath (alemtuzumab), according to Evercore ISI analyst Umer Raffat.
More from news
Approximately 7 fully matching, plus 25 partially matching documents found.
such as Aubagio (teriflunomide) and Lemtrada (alemtuzumab).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...